CD274 and pancreatic neoplasm: It is currently under investigation in the DRAGON trial (NCT04291079), a phase 1 clinical trial investigating it as a monotherapy or in combination with anti-PD-L1 in patients with solid tumors, including pancreatic tumors, which has shown no dose-limiting toxicity and adverse effects limited to fatigue, anorexia, and nausea.